Merit Medical Appoints New Chair and Reports Preliminary Revenue for Q4 2025
SOUTH JORDAN, Utah, Jan. 8, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI) has announced a significant leadership change by appointing F. Ann Millner, Ed.D., as the new Chair of the Board of Directors. This decision, effective January 5, 2026, follows the resignation of Fred P. Lampropoulos, who has been a foundational figure at Merit since its inception.
Leadership Transition at Merit Medical
Dr. Millner has been a director at Merit since 2015 and served as Lead Independent Director since July 2021. Prior to this appointment, she led the Governance and Sustainability Committee. In addition to her role at Merit, Dr. Millner has been a member of the Utah State Senate since 2015 and was President of Weber State University from 2002 to 2012.
On January 4, 2026, Fred P. Lampropoulos officially resigned from his position as director and Chair of the Board, as outlined in the Company’s CEO Transition Agreement. His exit follows his resignation as President and CEO on October 3, 2025.
Statements from Leadership
Lampropoulos, reflecting on his nearly four-decade tenure, stated, “As I step down after 38 years since founding Merit, I am proud of how far we’ve come and believe the company is stronger than ever.” He expressed confidence in the management team and Board as they guide Merit’s talented employees toward achieving the company’s goals.
Dr. Millner emphasized the impact of Lampropoulos’ leadership, saying, “Fred’s vision and leadership have been instrumental in building Merit into the global healthcare company it is today.” She assured stakeholders that the company remains committed to executing its Continued Growth Initiatives, focusing on financial targets through December 31, 2026.
Preliminary Revenue Results for Fourth Quarter 2025
Merit Medical has also announced its projected preliminary unaudited revenues for the fourth quarter of 2025, which are estimated to be between $389 million and $395 million. This represents a year-over-year growth ranging from 10% to 11%. Additionally, the preliminary unaudited constant currency revenue is expected to increase by approximately 8% to 10% year-over-year.
The Company will present the final financial results for the fourth quarter and full year ending December 31, 2025, along with guidance for fiscal year 2026, on February 24, 2026.
Investor Conference Call Details
Merit Medical has scheduled an investor conference call for February 24, 2026, at 4:30 p.m. Eastern Time. Participants can pre-register for the call to receive dial-in details. A live webcast of the call will also be available for those who prefer to join online. Further information can be found on Merit’s official website at www.merit.com.
Understanding Non-GAAP Financial Measures
Merit’s management utilizes non-GAAP financial measures, such as constant currency revenue, to provide a clearer view of the operational performance and underlying business trends. Despite the utility of such measures for evaluating profitability and efficiency, stakeholders are encouraged to review these figures alongside traditional GAAP measures.
About Merit Medical
Founded in 1987, Merit Medical Systems, Inc. specializes in the development, manufacture, and distribution of medical devices used across various healthcare sectors, including cardiology, radiology, and oncology. The company operates globally, supported by a dedicated team of over 7,500 employees worldwide.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the securities regulations. These statements address future events, including financial performance and strategic initiatives, and are inherently subject to risks and uncertainties.